Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a single dose, dose-escalation study to assess the safety, tolerability,
pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as
a disease modifying treatment for Alzheimer's disease.